Supplements
coffee decreases Parkinson's disease risk
In plain terms: Does coffee protect against Parkinson's disease?
Strong support Supplements 🔬 Includes disconfirming
Part of: • Coffee
RefutedContestedStrong support
consensus score 0.75
Coffee drinkers do get Parkinson's less often - studies suggest around 25-30% lower risk, likely via caffeine's effect on the brain. One honest caveat: very early Parkinson's can quietly reduce someone's taste for coffee years before diagnosis, which may make coffee look more protective than it truly is.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
8 support 2 contradict 1 tested null 2 mixed · 13 sources, 10 independent groups
What the evidence shows
People who drink coffee are consistently found to have a lower risk of Parkinson's disease — multiple meta-analyses and umbrella reviews put the risk around 25–30% lower, with the biggest effect near ~3 cups/day, anchored by the landmark Honolulu Heart cohort. The effect is thought to come from caffeine's action on brain adenosine receptors.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Hong CT, Chan L, Bai CH 2020 · Nutrients | meta-analysis | supports | high | Meta 13 studies: regular caffeine/coffee HR 0.797 lower PD risk; also slower progression. |
| Gabbert C, Blöbaum L, Lüth T, König IR, Caliebe A, Sendel S, Laabs BH, Klein C, Trinh J 2024 · Mov Disord | observational | mixed | moderate | Cohort: coffee among lifestyle factors predicting later PD age-at-onset (not incidence). |
| d10-31435-ijitss-2-50-2026-5914 2026 · International Journal of Innovative Technologies in Social Science | meta-analysis | supports | moderate | Explicit systematic review of epidemiological, preclinical and mechanistic evidence on coffee constituents and neurodegeneration; reports coffee/caffeine consumption correlates with PD risk reduction with relative risk ranging 0.65-0.80 acr |
| Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A 2010 · J Alzheimers Dis | meta-analysis | supports | high | SR+meta 26 studies: summary RR 0.75; cohort-only RR 0.80. |
| Kishore A, Borgohain R, Puthenveedu DK, Rajan R, Pal PK, Kandadai RM, Yadav R, Mehta S, Kumar H, Kumar N, Kukkle PL, Desai S, Shetty K, Wadia P, Aggarwal A, Agarwal PA, Abbas MM, Krishnan S, Madathiparambil Radhakrishnan D, Wali GM, Srivastava A, Kamble N, Ferreira TMDC, Lal V, Kumar Sreelatha AA, Gonzalez-Ricardo LG, Chacko M, Sharma M 2025 · Movement disorders : official journal of the Movement Disorder Society | observational | contradicts | moderate | Pan-Indian case-control study (7918 PD cases, 3300 age/sex-matched pairs): coffee consumption OR 1.73 among PD cases, explicitly flagged as an exception to the 'previously known' protective association seen elsewhere. |
| Kuzovenkova D, Liu L, Gan-Or Z, Senkevich K 2025 · Annals of clinical and translational neurology | observational | contradicts | moderate | Mendelian randomization found coffee consumption causally associated with LATER age-at-onset of PD (IVW OR 1.91, 95% CI 1.53-2.38, p=8e-9), but NO causal association or genetic correlation with PD risk or progression. |
| Mentis AA, Dardiotis E, Efthymiou V, Chrousos GP 2021 · BMC Med | meta-analysis | supports | high | Meta-umbrella of umbrella reviews: '14 umbrella reviews (203 unique meta-analyses) were eligible.' Reports 'In Parkinson disease (PD) and AD/dementia, coffee consumption, and physical activity were protective factors'; the coffee-PD row is inherited from Poole 2017, which re-reports Qi 2014: 'RR 0.64 (0.53–0.76) Parkinson disease (Qi, 2014)'. Third-order synthesis of data already counted (cof-qi-2013) — zero weight as review. |
| Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR 2000 · JAMA | observational | supports | high | Honolulu Heart cohort (8,004 men): PD incidence fell 10.4 to 1.9/10,000 from none to highest intake (landmark). |
| Chen Y, Sun X, Lin Y, Zhang Z, Gao Y, Wu IXY 2021 · J Parkinsons Dis | meta-analysis | supports | moderate | Overview of 46 systematic reviews ('Pooled effect estimations were extracted from each meta-analysis'; 39/46 SRs 'critically low methodological quality'). Coffee row re-reports an included meta-analysis: 'coffee (pooled RR: 0.67, 95%CI: 0.58 to 0.76', I2 42.9%, 19 case-control and cohort studies (from Qi & Li 2014 [37], = vault cof-qi-2013). Coffee and caffeine have separate estimates (not pooled with tea). Umbrella of syntheses — zero weight as review. |
| Gabbert C, König IR, Lüth T, Kolms B, Kasten M, Vollstedt EJ, Balck A, Grünewald A, Klein C, Trinh J 2022 · J Neurol | observational | tested-null | low | Cross-sectional (36k): coffee linked to later age-at-onset (not an incidence-risk design). |
| Trezzi I, Rizzo G, Giampieri F, Battino M, Baroni L 2026 · Foods (Basel, Switzerland) | observational | supports | low | Narrative review states 'moderate coffee consumption could reduce PD risk and progression' as part of a broader survey of diet and PD, without primary quantitative data of its own. |
| Grosso G, Godos J, Galvano F, Giovannucci EL 2017 · Annu Rev Nutr | meta-analysis | supports | high | 'we performed an umbrella review of the evidence from meta-analyses of observational studies and randomized controlled trials (RCTs)' — 59 unique outcomes across 112 meta-analyses of observational studies. Coffee showed 'a probable decreased risk of ... Parkinson's disease'; separately, in the 20-meta-analysis caffeine arm, 'caffeine was associated with a probable decreased risk of Parkinson's disease and type-2 diabetes'. Direction is consistent with the claim but is a summary of other syntheses, not new evidence. |
| Qi H, Li S 2014 · Geriatr Gerontol Int | meta-analysis | supports | high | Dose-response meta (901k): max protection ~3 cups/d, smoking-adjusted RR 0.72. |
| Zhao Y, Lai Y, Konijnenberg H, Huerta JM, Vinagre-Aragon A, Sabin JA, Hansen J, Petrova D, Sacerdote C, Zamora-Ros R, Pala V, Heath AK, Panico S, Guevara M, Masala G, Lill CM, Miller GW, Peters S, Vermeulen R 2024 · Neurology | observational | supports | high | EPIC4PD prospective cohort (n=184,024): highest vs. no coffee intake HR 0.63 (95% CI 0.46-0.88, p=0.006) for incident PD; nested case-control (351 cases) showed prediagnostic plasma caffeine and metabolites (paraxanthine, theophylline) inve |
| Ishihara L, Brayne C 2005 · Acta Neurol Scand | meta-analysis | supports | moderate | SR (7 cohort + 33 case-control): meta supports inverse coffee-PD association. |
| Saarinen EK, Kuusimäki T, Lindholm K, Niemi K, Honkanen EA, Noponen T, Seppänen M, Ihalainen T, Murtomäki K, Mertsalmi T, Jaakkola E, Myller E, Eklund M, Nuuttila S, Levo R, Chaudhuri KR, Antonini A, Vahlberg T, Lehtonen M, Joutsa J, Scheperjans F, Kaasinen V 2024 · Annals of neurology | observational | mixed | moderate | In 163 early PD patients, higher habitual coffee/caffeine consumption was associated with 8.3-15.4% lower striatal dopamine transporter binding and progressive decline over 6.1 years, with no effect on motor symptoms; authors interpret this |
| Hong SW, Page R, Truman P 2025 · Neurotoxicology | mechanism | supports | moderate | Narrative review: 'The aim of this review was to explore candidate molecules and mechanisms ... by integrating findings from previous studies'; suggests coffee/tobacco phenolics 'may contribute to the low incidence of PD' (MAO-B, COMT, alpha-synuclein targets). No own data — review, zero weight. |
| Chuang YH, Lill CM, Lee PC, Hansen J, Lassen CF, Bertram L, Greene N, Sinsheimer JS, Ritz B 2016 · Parkinsonism Relat Disord | observational | supports | moderate | Case-control + meta: inverse coffee-PD strongest in ADORA2A/CYP1A2 variant carriers. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.